Search results for "Agoni"

showing 10 items of 2493 documents

Exposure to gp120 of HIV-1 induces an increased release of arachidonic acid in rat primary neuronal cell culture followed by NMDA receptor-mediated n…

1995

After incubation of highly enriched neurons from rat cerebral cortex with the HIV-1 coat protein gp120 for 18 h, cells showed fragmentation of DNA at internucleosomal linkers followed by NMDA receptor-mediated neurotoxicity. We report that in response to exposure to gp120 cells react with an increased release of arachidonic acid (AA) via activation of phospholipase A2. This process was not inhibited by NMDA receptor antagonists. To investigate the role of AA on the sensitivity of the NMDA receptor towards its agonist, low concentrations of NMDA were co-administered with AA. This condition enhanced the NMDA-mediated cytotoxicity. Administration of mepacrine reduced cytotoxicity caused by gp1…

Agonistmedicine.drug_classNeurotoxinsPharmacologyHIV Envelope Protein gp120Receptors N-Methyl-D-Aspartatechemistry.chemical_compoundPhospholipase A2medicineAnimalsFragmentation (cell biology)Rats WistarCytotoxicityCells CulturedNeuronsArachidonic AcidbiologyCell DeathGeneral NeuroscienceNeurotoxicitymedicine.diseaseRatsnervous systemchemistryCell cultureQuinacrinebiology.proteinHIV-1NMDA receptorArachidonic acidDNA DamageThe European journal of neuroscience
researchProduct

Selection and characterization of a novel agonistic human recombinant anti-Trail-R2 minibody with anti-leukemic activity

2009

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising natural anticancer therapeutic agent because through its “death receptors”, TRAIL-R1 and TRAIL-R2, it induces apoptosis in many transformed tumor cells, but not in the majority of normal cells. Hence, agonistic compounds directed against TRAIL death receptors have the potential of being excellent cancer therapeutic agents, with minimal cytotoxicity in normal tissues. Here, we report the selection and characterization of a new single-chain fragment variable (scFv) to TRAIL-R2 receptor isolated from a human phage-display library, produced as minibody (MB), and characterized for the in vitro anti-leukemic tumoricid…

Agonistmedicine.drug_classTRAIL; TRAIL-R2; minibody; anticancer therapyImmunologylymphoma; therapy; recombinant antibodyTRAILApoptosislymphomaCHO CellsCricetulusPeptide LibraryTRAIL-R2CricetinaeImmunoglobulin FragmentmedicineAnimalsHumansImmunology and Allergyrecombinant antibodyanticancer therapyReceptorCytotoxicityImmunoglobulin FragmentsPharmacologytherapyLeukemiaChemistryAnimalChinese hamster ovary cellAntibody-Dependent Cell CytotoxicityminibodyApoptosiIn vitroRecombinant ProteinsReceptors TNF-Related Apoptosis-Inducing LigandCHO CellCell cultureApoptosisImmunologyCancer researchTumor necrosis factor alphaCricetuluHuman
researchProduct

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model…

2009

Parkinson's disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-ind…

Agonistmedicine.drug_classbusiness.industryPars compactaGeneral NeuroscienceMPTPCannabinoid Receptor AgonistsSubstantia nigraPharmacologynervous system diseaseschemistry.chemical_compoundnervous systemchemistryDopaminemedicineCannabinoid receptor type 2MPTP Poisoninglipids (amino acids peptides and proteins)businessmedicine.drugEuropean Journal of Neuroscience
researchProduct

Adrenoceptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

2019

The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [58], see also [180]. Adrenoceptors, α1α1-Adrenoceptors are activated by the endogenous agonists (-)-adrenaline and (-)-noradrenaline. phenylephrine, methoxamine and cirazoline are agonists and prazosin and cirazoline antagonists considered selective for α1- relative to α2-adrenoceptors. [3H]prazosin and [125I]HEAT (BE2254) are relatively selective radioligands. S(+)-niguldipine also has high affinity for L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bodipy PLprazosin- QAPB) are used to examine cellular localisation of α1-adrenoceptors. Selective α1-adrenoceptor agonists are use…

Agonistmedicine.drug_classbusiness.industryRauwolscinePropranololPharmacologyAtenololYohimbinechemistry.chemical_compoundchemistryBisoprololSympatholyticmedicinePrazosinbusinessmedicine.drugIUPHAR/BPS Guide to Pharmacology CITE
researchProduct

Endothelin receptors mediating contraction in goat cerebral arteries

1993

1. The aim of the present study was to identify the subtype of receptor mediating contraction to endothelin-1 and sarafotoxin S6b in goat isolated middle cerebral arteries. 2. Endothelin-1, endothelin-2 and endothelin-3 contracted cerebral arteries in a concentration-dependent manner. Although the three peptides were full agonists, the order of potency was endothelin-1 = endothelin-2 > endothelin-3, with a relative potency of endothelin-1 and endothelin-2 versus endothelin-3 of approximately 280. Sarafotoxin S6b induced concentration-dependent contractions with lower potency than endothelin-1/endothelin-2, higher potency than endothelin-3 and a higher maximum response than the three endothe…

Agonistmedicine.hormoneSerotoninmedicine.medical_specialtymedicine.drug_classMolecular Sequence DataCerebral arteriesViper VenomsIn Vitro TechniquesPeptides Cycliccomplex mixturesMuscle Smooth VascularEndothelinschemistry.chemical_compoundInternal medicinemedicine.arterymedicineAnimalsVasoconstrictor AgentsPotencyAmino Acid SequencePharmacologyBQ-123Receptors EndothelinChemistryEndothelinsGoatsCerebral ArteriesEndocrinologyMiddle cerebral arterycardiovascular systemFemalemedicine.symptomEndothelin receptorVasoconstrictionResearch ArticleMuscle ContractionBritish Journal of Pharmacology
researchProduct

Subtype-Specific Desensitization of Human Endothelin ETA and ETB Receptors Reflects Differential Receptor Phosphorylation

1997

Endothelins regulate blood pressure in mammals through G protein-coupled receptors. Two receptor subtypes, ETA and ETB, exist which differ by their agonist profiles. Here we show subtype-specific differences in the inactivation of these endothelin receptors. Using a modified inositol phosphate accumulation assay, we found that stimulation of ETA by endothelin-1 results in sustained activation of the subtype, retaining >30% of its initial activity even 20 min after agonist administration, whereas the ETB rapidly deactivated after agonist stimulation, losing >80% of its initial activity within 5 min after endothelin application. The discrepancy in receptor inactivation is reflected by subtype…

Agonistmedicine.hormonemedicine.medical_specialtyEndothelin receptor type Amedicine.drug_classmedia_common.quotation_subjectStimulationCHO CellsPalmitic AcidsSpodopteraLigandsBiochemistryEndothelinsCricetinaeInternal medicinemedicineAnimalsHumansPhosphorylationInternalizationReceptorProtein Kinase Cmedia_commonReceptors EndothelinChemistryImmune Serarespiratory systemReceptor Endothelin AReceptor Endothelin BKineticsEndocrinologycardiovascular systemPhosphorylationEndothelin receptorcirculatory and respiratory physiologyBiochemistry
researchProduct

ATP and endogenous agonists inhibit evoked [3H]-noradrenaline release in rat iris via A1 and P2y-like purinoceptors.

1993

Effects of ATP, adenosine and purinoceptor antagonists on field stimulation-evoked (3 Hz, 2 min) [3H]-noradrenaline overflow were investigated in the rat isolated iris. ATP and adenosine inhibited the evoked overflow of [3H]-noradrenaline. 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX) shifted the concentration-response curve of ATP to the right in a concentration-dependent manner, but with a potency (-log KB = 7.88) much lower than expected for an A1 adenosine receptor. In the continuous presence of DPCPX, the ATP-induced prejunctional inhibition was unaffected by suramin (100 mumol/l) and DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid, 50 mumol/l) but was antagonized by the P2Y-rece…

Agonistmedicine.medical_specialtyAdenosinemedicine.drug_classSuraminIrisSuraminBiologyP2 receptor44'-Diisothiocyanostilbene-22'-Disulfonic AcidIn Vitro TechniquesSynaptic Transmissionchemistry.chemical_compoundNorepinephrineAdenosine TriphosphateInternal medicinemedicinePurinergic P2 Receptor AntagonistsAnimalsRats WistarPharmacologyProtein Synthesis InhibitorsReceptors Purinergic P2TriazinesPurinergic receptorReceptors Purinergic P1General MedicineAdenosine receptorAdenosineElectric StimulationRatsEndocrinologychemistryPurinergic P1 Receptor AntagonistsDIDSXanthinesAutoreceptormedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

Adrenergic activation of phospholipase D in primary rat astrocytes.

1996

Phospholipase D (PLD) activity was investigated in astrocytes prepared from newborn rat cerebral cortex using the transphosphatidylation assay. Basal PLD activity was measurable and was found to be enhanced by ATP, carbachol and noradrenaline. The activation by noradrenaline (EC50, 0.68 microM) was mimicked by methoxamine (EC50, 65 microM), an alpha 1-specific adrenergic agonist, and was inhibited by prazosine, an alpha 1-specific adrenergic antagonist. Clonidin, an alpha 2-adrenergic agonist, slightly lowered PLD activity whereas beta-adrenergic drugs were without effect. Experiments with mitogens indicate that PLD activation in astrocytes may be involved in the control of astrocytic cell …

Agonistmedicine.medical_specialtyCarbacholmedicine.drug_classAdrenergicBiologyMethoxamineMethoxamineNorepinephrineInternal medicinemedicineAdrenergic antagonistPhospholipase DAnimalsAdrenergic agonistCells CulturedDose-Response Relationship DrugPhospholipase DGeneral NeuroscienceRatsenzymes and coenzymes (carbohydrates)Endocrinologymedicine.anatomical_structureAstrocytesNeuroglialipids (amino acids peptides and proteins)medicine.drugNeuroscience letters
researchProduct

Endothelin Antagonism: Effects of FP Receptor Agonists Prostaglandin F2αand Fluprostenol on Trabecular Meshwork Contractility

2006

Purpose This study analyzes additional mechanisms behind the ocular hypotensive effect of prostaglandin F (PGF) receptor (FP receptor) agonists PGF2alpha and fluprostenol (fluprostenol-isopropyl ester [travoprost]), which reduce intraocular pressure (IOP) in patients with glaucoma probably by enhancing uveoscleral flow. The trabecular meshwork (TM) is actively involved in IOP regulation through contractile mechanisms. Contractility of TM is induced by endothelin (ET)-1, a possible pathogenic factor in glaucoma. The involvement of FP receptor agonists in the ET-1 effects on TM function was studied. Methods The effects of FP receptor agonists on contractility of bovine TM (BTM) were investiga…

Agonistmedicine.medical_specialtyCarbacholmedicine.drug_classBlotting WesternReceptors ProstaglandinDinoprostContractilityTravoprostTrabecular MeshworkInternal medicinemedicineAnimalsReceptorCells CulturedEndothelin-1ChemistryCloprostenolMuscle SmoothEndothelin 1medicine.anatomical_structureProstaglandin F2alphaEndocrinologyCalciumCattleTrabecular meshworkFura-2Endothelin receptorMuscle Contractionmedicine.drugInvestigative Opthalmology & Visual Science
researchProduct

Acetylcholine and nicotine stimulate the release of granulocyte-macrophage colony stimulating factor from cultured human bronchial epithelial cells.

1998

Primary cultures of human bronchial epithelial cells (HBE-cells) were established to measure granulocyte-macrophage colony stimulating factor (GM-CSF) release. HBE-cells showed a basal GM-CSF release (82+/-20 ng/well/24 h; 30 donors), which was increased by interleukin-1 beta(IL-1beta, 1 ng/ml) by 270%. This effect was blocked by 1 microM dactinomycin or 10 microM cycloheximide, i.e. the stimulatory effect of IL-1beta depended on de-novo synthesis. Histamine (100 microM) and acetylcholine ( 100 nM) stimulated GM-CSF release more than two-fold above the baseline. Nicotine (1 microM) increased GM-CSF release to a similar extent, and this effect was prevented by 30 microM (+)-tubocurarine. The…

Agonistmedicine.medical_specialtyNicotinemedicine.drug_classSubstance PBronchiCycloheximideBiologyNicotinechemistry.chemical_compoundInternal medicineMuscarinic acetylcholine receptormedicineOxotremorineHumansNicotinic AgonistsCells CulturedPharmacologyGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineAcetylcholineEndocrinologychemistryHistamineAcetylcholinemedicine.drugHistamineNaunyn-Schmiedeberg's archives of pharmacology
researchProduct